← All trials
NCT06721299
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2025
- Primary completion
- Feb 29, 2028
- Completion date
- Jul 31, 2028
- First posted
- Dec 6, 2024
- Last posted
- Dec 6, 2024
- Enrollment
- 30
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of KansasLead sponsor
- University of KansasSponsor investigator
- University of RochesterCollaborator
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Collaborator
- University of WashingtonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.